Allergan (AGN) says Darpin data does not support Phase 3 trials.
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
UPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regenxbio shares jump after FDA agrees to reverse drug rejection
- Trump praises IBM CEO
- Meta pausing an internal AI training program after sensitive data was accessible across the entire company - Business Insider
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
